Glomeruloid Microvascular Proliferation Is Superior to Intratumoral Microvessel Density as a Prognostic Marker in Non-Small Cell Lung Cancer

Fumihiro Tanaka, Hiroki Oyanagi, Kazumasa Takenaka, Shinya Ishikawa, Kazuhiro Yanagihara, Ryo Miyahara, Yozo Kawano, Mio Li, Yusuke Otake, and Hiromi Wada

INTRODUCTION

Angiogenesis is an essential process in development and progression of a variety of malignant tumors including NSCLC, and it is generally recognized that angiogenesis can be a new marker and target in the diagnosis and therapy (1, 2). IMVD is usually used in the evaluation of angiogenesis, but some clinical studies did not show the correlation between vascular endothelial growth factor and the incidence of GMPs. GMPs and IMVD were more frequently seen in Ang-1-positive tumor than in Ang-1-negative tumor. The 5-year survival rate of GMP-positive patients was 52.4%, which was significantly lower than that of GMP-negative patients (72.3%; P = 0.016). The 5-year survival rate of higher-MVD patients (71.5%) seemed to be lower than that of the lower-MVD patients (63.7%), but the difference did not reach a statistical significance (P = 0.137). A multivariate analysis confirmed that the presence of GMPs was a significant prognostic factor (P = 0.003), whereas MVD was not. In conclusion, GMPs indicate an aggressive angiogenic phenotype associated with a poor prognosis in NSCLC.

MATERIALS AND METHODS

Patients and Tissue Preparation. A total of 237 consecutive patients with p-stage I to IIIA NSCLC, who underwent complete resection without any preoperative therapy at Kyoto University Hospital from January 1, 1985 through December 31, 1990, were retrospectively reviewed. One patient was excluded from the study because of operation-related death, and a final total of 236 patients were evaluated (Table 1; Refs. 6, 13, 14). P-stage was re-evaluated and determined with the current tumor-node-metastasis classification (15), and histological type was also determined with the current classification by WHO (16).

For all of these patients, the inpatient medical records, chest X-ray films, whole-body computed tomography films, bone scanning data, and records of surgery were reviewed. Intraoperative therapy was not performed in any patient. As postoperative adjuvant therapy, cisplatin-based chemotherapy, radiation, and oral administration of tegafur (a fluorouracil derivative drug) were prescribed for 55, 35, and 58 patients, respectively (13). Follow-up of the postoperative clinical course was conducted by outpatient medical records and by inquiries by telephone or letter. This study was reviewed and approved by the “Ethics Committee, Graduate School and Faculty of Medicine, Kyoto University.”

Serial 4-μm formalin-fixed and paraffin-embedded sections were prepared from each tumor sample, and were served for routine H&E staining, IHS, and the terminal deoxynucleotidyltransferase-mediated nick end labeling staining. Results of IHS were evaluated by two authors independently (F. T. and S. I.) without knowledge of any clinical data.

Identification of GMPs and Quantification of Angiogenesis (IMVD). ECs were highlighted with an anti-CD34 antibody, and GMPs were positive in 60 (25.4%) patients, and the incidence was not correlated with age, gender, histological type, or p-stage. The mean intratumoral microvessel densities for GMP-negative tumor and GMP-positive tumor were 178.2 and 184.1, respectively, showing that the difference did not reach a statistical significance (P = 0.137). A multivariate analysis confirmed that the presence of GMPs was a significant prognostic factor (P = 0.003), whereas MVD was not. In conclusion, GMPs indicate an aggressive angiogenic phenotype associated with a poor prognosis in NSCLC.

ABSTRACT

Glomeruloid microvascular proliferation (GMP) is a focal proliferative budding of endothelial cells (ECs) resembling a renal glomerulus. Whereas some experimental and clinical studies have suggested recently that GMPs indicate an aggressive angiogenic phenotype, the incidence and clinical significance of GMPs remains unclear. Thus, we conducted a retrospective study on GMPs in a total of 236 patients with completely resected pathological (p-) stage I-IIIA NSCLC. ECs were highlighted with immunohistochemical staining using an anti-CD34 antibody, and GMPs were defined as focal glomerulus-like aggregates of closely associated and multilayer CD34-positive ECs. Expression of vascular endothelial growth factor, angiopoietin (Ang)-1, and Ang-2 was also examined immunohistochemically. GMPs were positive in 60 (25.4%) patients, and the incidence was not correlated with age, gender, histological type, or p-stage. The mean intratumoral microvessel densities for GMP-negative tumor and GMP-positive tumor were 178.2 and 184.1, respectively, showing that the difference did not reach a statistical significance (P = 0.137). A multivariate analysis confirmed that the presence of GMPs was a significant prognostic factor (P = 0.003), whereas MVD was not. In conclusion, GMPs indicate an aggressive angiogenic phenotype associated with a poor prognosis in NSCLC.

Received 6/30/03; revised 7/22/03; accepted 7/24/03.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by Grants-in-Aid 14370410 (to F. T.) and 15390411 (to F. T. and H. W.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

To whom requests for reprints should be addressed, at Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Shogoin-kawahara-cho 54, Sakyo-ku, Kyoto 606-8507, Japan. Phone: 81-75-751-4975; Fax: 81-75-751-4974; E-mail: ftanaka@kuhp.kyoto-u.ac.jp.

The abbreviations used are: NSCLC, non-small cell lung cancer; GMP, glomeruloid microvascular proliferation; Ang, angiopoietin; VEGF, vascular endothelial growth factor; IMVD, intratumoral microvessel density; EC, endothelial cell; Ad, adenocarcinoma; Sq, squamous cell carcinoma; mAb, monoclonal antibody; p, pathological; IHS, immunohistochemical staining; PI, proliferative index; AI, apoptotic index.
Table 1 Characteristics of patients and GMP in NSCLC

<table>
<thead>
<tr>
<th>No. of patients (%)</th>
<th>GMP-negative</th>
<th>GMP-positive</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients</td>
<td>236 (100%)</td>
<td>176 (74.6%)</td>
<td>0.049</td>
</tr>
<tr>
<td>Age (mean ± SD)</td>
<td>62.4 ± 9.7</td>
<td>62.7 ± 9.6</td>
<td>61.7 ± 10.0</td>
</tr>
<tr>
<td>Male</td>
<td>170 (72.0%)</td>
<td>128 (75.3%)</td>
<td>42 (24.7%)</td>
</tr>
<tr>
<td>Female</td>
<td>66 (28.0%)</td>
<td>48 (72.7%)</td>
<td>18 (27.3%)</td>
</tr>
<tr>
<td>Performance status</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Positive</td>
<td>206 (87.3%)</td>
<td>156 (75.7%)</td>
<td>50 (24.3%)</td>
</tr>
<tr>
<td>Negative</td>
<td>28 (11.9%)</td>
<td>19 (67.9%)</td>
<td>9 (32.1%)</td>
</tr>
<tr>
<td>Histologic type</td>
<td>Sq</td>
<td>Ad</td>
<td>Others</td>
</tr>
<tr>
<td>Sq</td>
<td>85 (36.0%)</td>
<td>94 (72.3%)</td>
<td>36 (27.7%)</td>
</tr>
<tr>
<td>Ad</td>
<td>130 (55.1%)</td>
<td>12 (92.3%)</td>
<td>1 (7.7%)</td>
</tr>
<tr>
<td>Others</td>
<td>13 (5.5%)</td>
<td>5 (62.5%)</td>
<td>3 (37.5%)</td>
</tr>
<tr>
<td>p-stage</td>
<td>I</td>
<td>II</td>
<td>IIIA</td>
</tr>
<tr>
<td>I</td>
<td>138 (58.5%)</td>
<td>101 (73.2%)</td>
<td>37 (26.8%)</td>
</tr>
<tr>
<td>II</td>
<td>26 (11.0%)</td>
<td>17 (65.4%)</td>
<td>9 (34.6%)</td>
</tr>
<tr>
<td>IIIA</td>
<td>72 (30.5%)</td>
<td>58 (80.6%)</td>
<td>14 (19.4%)</td>
</tr>
</tbody>
</table>

The mean IMVDs for GMP-negative and GMP-positive tumors were 178.2 and 184.1, respectively, which showed that there was no correlation between the presence of GMPs and IMVD (Table 2). No significant correlation between the presence of GMPs and the status of VEGF or Ang-2 was documented (Table 2). However, the incidence of positive GMP was significantly higher in Ang-1-positive tumors than in Ang-1-negative tumors (55.0% versus 38.6%; P = 0.034; Table 2).

There was no significant difference in PI or AI between GMP-negative and GMP-positive tumors (Table 2).

GMPs and Postoperative Survival. The 5-year survival rate for GMP-negative patients was 72.3%, significantly higher than that for GMP-positive patients (54.2%; P = 0.016; Fig. 2; Table 3). In contrast, there proved to be no significant difference in the postoperative prognosis between the lower IMVD patients (IMVD <157) and the higher IMVD patients (IMVD ≥157), although the 5-year survival rate of the lower IMVD group (71.5%) seemed to be higher than that of the higher IMVD group (63.7%; P = 0.137).

Next, analyses of postoperative survival stratified by p-stage or histological type were performed (Table 3). For p-stage I disease, the 5-year survival rate for GMP-positive patients was significant lower than that for GMP-negative patients (62.9% versus 84.8%; P = 0.018; Fig. 3). For Ad, there was a significant difference in the postoperative survival between GMP-positive and -negative patients (Fig. 4).

A multivariate analysis confirmed that the presence of GMPs was a significant factor to predict a poor prognosis and that VEGF status or IMVD was not a significant prognostic factor (Table 4).
DISCUSSION

In the present study, we first demonstrated that GMPs were present in one quarter of NSCLC, and that the presence of GMPs was a significant factor to predict a poor prognosis. These findings are entirely consistent with results documented in other malignant tumors such as breast cancer (9), which strongly suggest that GMPs are useful markers of aggressive angiogenesis in a variety of malignant tumors. Tumor angiogenesis is generally evaluated with IMVD, and many clinical studies have revealed that higher IMVDs are significant factors to predict poor prognoses in malignant tumors including NSCLC (17). However, some clinical studies failed to document the prognostic significance of IMVD (3, 4, 5, 6), and the clinical significance of IMDV has not been established. In the present study, we failed to document a prognostic significance of IMVD, whereas we documented a significantly poor prognosis for positive GMPs tumors. These results suggest that GMPs are superior to IMVD in the evaluation of tumor angiogenesis.

In the present study, the presence of GMPs was not correlated with IMVD; the mean IMVDs for GMP-negative tumor and GMP-positive tumor were 178.2 and 184.1. One of the probable reasons why IMVD was not a significant prognostic factor or was not correlated with the presence of GMPs may be the variability in the reactivity of anti-EC antibodies used to highlight intratumoral microvessels (18, 19). Antibodies against pan-EC markers including CD34 are not entirely specific for ECs (20, 21), and these pan-EC antibodies may not be an ideal reagent to visualize tumor-associated blood vessels, because pan-EC antibodies react not only with newly forming vessels but also stable vessels just trapped in tumors. ECs in GMPs that are highlighted with an anti-CD34 antibody may be layered "activated" vessels.

We demonstrated that the presence of GMPs was significantly correlated not with enhanced VEGF expression but with enhanced Ang-1 expression. Ang-1 and Ang-2 have been identified as ligands for Tie2, which is a receptor tyrosine kinase specifically expressed on ECs, and Angs play critical roles in angiogenesis in concert with VEGF (2). Ang-1 binds to Tie2, and maintains and stabilizes mature vessels by promoting interaction between ECs and surrounding extracellular matrix. Ang-2 competitively binds to Tie2, and antagonizes the stabilizing action of Ang-1, which result in destabilization of vessels. These destabilized vessels may undergo regression in the absence of angiogenic factors such as VEGF; however, in the presence of VEGF these destabilized vessels may undergo angiogenic changes. Thus, angiogenesis is controlled by dynamic balance between vessel regression and growth mediated by VEGF, Ang-1, and Ang-2 (2). Taken with these experimental results, enhanced expression of Ang-1 that stabilizes ECs is essential for the presence of GMPs. In contrast, enhanced expression of VEGF was not correlated with the presence of GMPs in the present study, which suggested that baseline or minimal VEGF might be adequate for the formation of...
GMPs. In conclusion, GMPs indicate an aggressive angiogenic phenotype and a novel prognostic factor in NSCLC.

ACKNOWLEDGMENTS

We thank Tomoko Yamada for excellent preparation of the sections. We also thank Seiko Sakai for helpful assistance for preparation of the manuscript.

REFERENCES


Glomeruloid Microvascular Proliferation Is Superior to Intratumoral Microvessel Density as a Prognostic Marker in Non-Small Cell Lung Cancer

Fumihiro Tanaka, Hiroki Oyanagi, Kazumasa Takenaka, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/63/20/6791

Cited articles
This article cites 19 articles, 6 of which you can access for free at:
http://cancerres.aacrjournals.org/content/63/20/6791.full.html#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/63/20/6791.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.